Live Breaking News & Updates on Lynn Malec

Stay updated with breaking news from Lynn malec. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Breaking Barriers in Bleeding Disorders: Experts Call for More Data on Women

“These autosomal diseases, from an inheritance standpoint, affect men and women equally, but because of their impact on the gynecological system and menses, women are often affected much more than men," hematologist Donna DiMichele, MD, explains. ....

United States , Lynn Malec , Margaret Ragni , States Vwdmin , Grossig Margaret Ragni , Donna Dimichele , Division Of Hematology Oncology , Foundation For Women , Versiti Blood Research Institute , National Institutes Of Health , Center On Health Equity , Hemophilia Center , Division Of Blood Diseases , Blood Institute , Womens Health Larchmt , College Of Wisconsin , American Society Of Hematology , National Heart , University Of Pittsburgh , Western Pennsylvania , American Society , American Journal , Health Equity , Comprehensive Center , Bleeding Disorders , Medical College ,

Altuviiio Children's Study Demonstrates Equivalent Outcomes

A yearlong study of the newly approved half-life extender showed no evidence of factor VIII inhibitors. ....

Jivi Bayer , Esperoct Novo Nordisk , Hemlibra Roche , Lynn Malec , Sanofi Genzyme , College Of Wisconsin , Versiti Blood Research Institute In Milwaukee , Weekly Factor , Novo Nordisk , Bill Sibold , Comprehensive Center , Versiti Blood Research Institute , Medical College ,

Lynn Malec, MD: FVIII Therapy Improves Levels in Pediatric Patients with Hemophilia A

Efaconescotog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy. ....

Lynn Malec , Drug Administration , Versiti Blood Research Institute , College Of Wisconsin , Comprehensive Center , Bleeding Disorders , Medical College , Breakthrough Therapy ,

Lynn Malec, MD: Efanesoctocog alfa Reduces Bleeds, Treatment Burden for Hemophilia

Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community. ....

Lynn Malec , College Of Wisconsin , Drug Administration , Versiti Blood Research Institute , International Society On Thrombosis , International Society , Comprehensive Center , Bleeding Disorders , Medical College , Breakthrough Therapy ,

Once-weekly Altuviiio offers bleed protection for children with severe hemophilia A

Once-weekly prophylaxis with a high-sustained factor VIII replacement therapy exhibited effective bleed protection for children with severe hemophilia A, according to the agent’s manufacturer.Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, Sanofi) is approved in the United States for routine prophylaxis and on-demand treatment to control bleeding episodes for ....

United States , Lynn Malec , Haemostasis Congress , International Society On Thrombosis , College Of Wisconsin , Versiti Blood Research Institute , International Society , Medical College , Comprehensive Center , Bleeding Disorders ,